Search...
/
The Fly Cast
Press play to listen
Competitive Advantages
Risks
Competitive Advantages
Proprietary Technology Platforms: Regeneron's unique VelocImmune mouse platform and Trap technology are foundational for discovering fully human monoclonal antibodies and soluble receptor proteins, respectively, providing a significant head start in drug development.
Proven R&D Engine and Pipeline: A track record of successful drug discovery and development, continually feeding a robust pipeline with potential future blockbusters across multiple therapeutic areas.
Established Blockbuster Products: Dependence on highly successful drugs like Eylea (eye diseases) and Dupixent (atopic dermatitis, asthma, etc.) provides substantial and stable revenue streams to reinvest.
Risks
Intensifying Competition for Key Products: Regeneron's blockbuster drug Eylea faces increasing competition from new entrants like Vabysmo and potential biosimilars, which could erode market share and revenue.
Clinical Trial Failures and Delays: The success of Regeneron's robust pipeline depends on positive outcomes from clinical trials; any failures or significant delays could hinder future growth and profitability.
Regulatory Approval Challenges: Despite successful clinical data, new drug candidates must navigate stringent regulatory approval processes by agencies like the FDA, with no guarantee of market authorization.
Thursday
Aug 6, 11:33 AM
Monday
Aug 3, 9:29 AM
Aug 3, 6:36 AM
Over a week ago
Jul 31, 9:07 AM
Jul 31, 8:57 AM
Jul 31, 8:25 AM
Jul 31, 7:22 AM
Jul 31, 6:17 AM
Jul 30, 8:17 AM
Jul 30, 6:31 AM
Jul 21, 8:01 AM
Jul 14, 5:03 PM
Jul 13, 7:15 AM
Jul 9, 7:13 AM
Jul 8, 7:39 AM
Jul 7, 9:13 AM
Jul 7, 7:26 AM
Jul 6, 10:25 AM
Jul 6, 7:05 AM
